JHU (Baltimore)

The Clinical Research Site at Johns Hopkins, directed by Sonya Krishnan, MD, occupies space on  the East Baltimore Medical Campus. The JHU CRS takes advantage of the many units available within Johns Hopkins Hospital, including Inpatient/Overnight Services for adult research participants, the Outpatient Research Unit, Inpatient/Outpatient Service for pediatric research participants, research nutrition services, and the Drug Development and Analysis Unit.

The HIV Care Program serves as the most important resource for patient referrals to ACTG clinical trials and is also an important referral source for HPTN trials. The Service was founded in 1983, and the principal components are summarized below:

Laboratory Facilities
All sample processing for virology assays for the CRS will be performed in the HIV Specialty Lab and includes a tissue culture room, specimen prep room, a PCR amplification room, a room for HIV antibody testing and a PCR detection room. The HIV/STD Research Laboratory is recognized internationally for expertise as a reference laboratory for all STDs, especially gonorrhea and chlamydia testing. Both the gonococcal and chlamydial sections of this laboratory are licensed by the State of Maryland and Clinical Laboratory Improvement Amendments (CLIA; ID # 21D0680509; State of Maryland laboratory permit #008 and 940247, respectively) for STD diagnostic evaluations, and are recognized as leading diagnostic labs in the United States.

Clinical Trials

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More

Impact of Tuberculosis Infection on HIV-1 Antibody Response...

Study Objective: Compare longitudinal HIV-1 antibody responses among HIV-1 infected participants that either did or did not...

Read More

ACTIV-2/A5401: Adaptive Platform Treatment for Outpatients...

Rationale: There is an urgent need for a platform to rapidly evaluate therapies in the outpatient setting, to prevent disease...

Read More

HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study...

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...

Read More